Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) EBIT (2016 - 2025)

Historic EBIT for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to -$20.9 million.

  • Altimmune's EBIT rose 1577.91% to -$20.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.5 million, marking a year-over-year increase of 1917.91%. This contributed to the annual value of -$103.2 million for FY2024, which is 755.04% down from last year.
  • Altimmune's EBIT amounted to -$20.9 million in Q3 2025, which was up 1577.91% from -$22.9 million recorded in Q2 2025.
  • Altimmune's EBIT's 5-year high stood at -$14.9 million during Q1 2021, with a 5-year trough of -$33.6 million in Q4 2023.
  • In the last 5 years, Altimmune's EBIT had a median value of -$23.1 million in 2022 and averaged -$23.7 million.
  • As far as peak fluctuations go, Altimmune's EBIT plummeted by 12312.05% in 2021, and later surged by 2604.47% in 2024.
  • Over the past 5 years, Altimmune's EBIT (Quarter) stood at -$24.0 million in 2021, then increased by 3.71% to -$23.1 million in 2022, then tumbled by 45.59% to -$33.6 million in 2023, then increased by 26.04% to -$24.9 million in 2024, then grew by 16.11% to -$20.9 million in 2025.
  • Its EBIT was -$20.9 million in Q3 2025, compared to -$22.9 million in Q2 2025 and -$21.8 million in Q1 2025.